Clinical trial NCT01365286 - References

Asthma, Chronic Obstructive Pulmonary Disease (COPD) — HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Citation(s)

•   Ageev FT, Makarova GV, Patrusheva IF, Orlova IaA
  [The efficacy and safety of the combination of ß-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease]. Kardiologiia. 2010;50(10):22-6. Russian.
•   Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R
  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997 Dec;10(12):2794-800.
•   Babu KS, Gadzik F, Holgate ST
  Absence of respiratory effects with ivabradine in patients with asthma. Br J Clin Pharmacol. 2008 Jul;66(1):96-101. doi: 10.1111/j.1365-2125.2008.03160.x. Epub 2008 Mar 13.
•   Benson MK, Berrill WT, Cruickshank JM, Sterling GS
  A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978 May;5(5):415-9.
•   Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group
  Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003 Feb 18;107(6):817-23.
•   Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P
  Asthma and comorbid medical illness. Eur Respir J. 2011 Jul;38(1):42-9. doi: 10.1183/09031936.00140310. Epub 2010 Dec 22.
•   Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ
  Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010 Mar;40(3):193-200. doi: 10.1111/j.1445-5994.2009.01943.x. Epub 2009 Mar 10.
•   Demontis GC, Longoni B, Barcaro U, Cervetto L
  Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol. 1999 Mar 15;515 ( Pt 3):813-28.
•   DiFrancesco D, Camm JA
  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757-65. Review.
•   Farrell MH, Foody JM, Krumholz HM
  beta-Blockers in heart failure: clinical applications. JAMA. 2002 Feb 20;287(7):890-7.
•   Fihn SD, Williams SV, Daley J, Gibbons RJ; American College of Cardiology; American Heart Association; American College of Physicians-American Society of Internal Medicine
  Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med. 2001 Oct 16;135(8 Pt 1):616-32.
•   Ford ES, Giles WH, Croft JB
  Prevalence of nonfatal coronary heart disease among American adults. Am Heart J. 2000 Mar;139(3):371-7.
•   Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group
  Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. Epub 2007 Aug 13. Review.
•   Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators
  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.
•   Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG)
  Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006 Jun;27(11):1341-81. Epub 2006 May 30.
•   Freemantle N, Cleland J, Young P, Mason J, Harrison J
  beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999 Jun 26;318(7200):1730-7.
•   Frishman WH, Furberg CD, Friedewald WT
  The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol. 1984 Jun;9(3):1-50. Review.
•   Gheorghiade M, Goldstein S
  Beta-blockers in the post-myocardial infarction patient. Circulation. 2002 Jul 23;106(4):394-8.
•   Gillum RF, Makuc DM, Feldman JJ
  Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991 Jan;121(1 Pt 1):172-7.
•   Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr
  Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990 Mar 1;65(9):547-53.
•   Kaneko A, Tachibana M
  A voltage-clamp analysis of membrane currents in solitary bipolar cells dissociated from Carassius auratus. J Physiol. 1985 Jan;358:131-52.
•   Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA
  Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987 Jun;113(6):1489-94.
•   Kjekshus JK
  Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57(12):43F-49F.
•   Lammers JW, Folgering HT, van Herwaarden CL
  Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S69-73.
•   Lechat P
  Beta-blocker treatment in heart failure. Role of heart rate reduction. Basic Res Cardiol. 1998;93 Suppl 1:148-55. Review.
•   Lipworth BJ, Irvine NA, McDevitt DG
  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur J Clin Pharmacol. 1991;40(5):467-71.
•   Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program
  The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59(5):469-78. Review.
•   Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S
  Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997 Nov;30(5):1267-73.
•   Roche N, Huchon G
  [Epidemiology of chronic obstructive pulmonary disease]. Rev Prat. 2004 Sep 15;54(13):1408-13. Review. French.
•   Salpeter SR, Ormiston TM, Salpeter EE
  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21.
•   Satoh TO, Yamada M
  A bradycardiac agent ZD7288 blocks the hyperpolarization-activated current (I(h)) in retinal rod photoreceptors. Neuropharmacology. 2000 Apr 27;39(7):1284-91.
•   Schwartz S, Davies S, Juers JA
  Life-threatening cold and exercise-induced asthma potentiated by administration of propranolol. Chest. 1980 Jul;78(1):100-1.
•   Sears MR
  Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S322-8. Review.
•   Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators
  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26(23):2529-36. Epub 2005 Oct 7.
•   Williams IP, Millard FJ
  Severe asthma after inadvertent ingestion of oxprenolol. Thorax. 1980 Feb;35(2):160.

Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Details for clinical trial NCT01365286